Apalutamide

Nanoform Q3 2024 report highlights record new non-GMP projects, revenue growth, and progress in GMP activities and product kernels. Key financials show revenue growth and increased gross profit, with ongoing manufacturing for pivotal studies and registration batches in Project Nanoenzalutamide. Dealmaking progress includes term sheets and LOIs, with expectations for license/commercial supply agreements. CEO's review emphasizes growth acceleration and strategic milestones achieved.

ERLEADA showed a statistically significant overall survival benefit at 24 months compared to enzalutamide in metastatic castration-sensitive prostate cancer patients, according to a real-world study presented at the 6th European Congress of Oncology Pharmacy.

The FDA's approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in 2022 has significantly impacted the treatment of prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC). This radioligand therapy, after other treatments like ARPIs and taxane-based chemotherapy, has shown life-prolonging effects and improved quality of life. Potential future applications include earlier use in the treatment paradigm and combination therapies, with ongoing research aiming to establish a broader role for this treatment type.